NICE reaches a deal with Roche on access to oral SMA drug Evrysdi
pharmaphorum
NOVEMBER 19, 2021
The cost-effectiveness agency had turned down Evrysdi (risdiplam) in draft guidance published in June, saying it was too expensive, but after negotiations with Roche has reached a deal that will make the drug available to around 1,500 people in England. million price tag make it is the most expensive treatment ever approved for NHS funding.
Let's personalize your content